
Christian Lorenz Althaus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4899776/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	13.7	1,210
2	Replacement of the Gamma by the Delta variant in Brazil: Impact of lineage displacement on the ongoing pandemic. Virus Evolution, 2022, 8, veac024.	2.2	37
3	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nature Medicine, 2022, 28, 1785-1790.	15.2	456
4	A Data-Driven Simulation of the Exposure Notification Cascade for Digital Contact Tracing of SARS-CoV-2 in Zurich, Switzerland. JAMA Network Open, 2021, 4, e218184.	2.8	25
5	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature, 2021, 595, 707-712.	13.7	363
6	Quantifying superspreading for COVID-19 using Poisson mixture distributions. Scientific Reports, 2021, 11, 14107.	1.6	17
7	Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Lancet Public Health, The, 2021, 6, e683-e691.	4.7	85
8	Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. Epidemics, 2021, 37, 100480.	1.5	34
9	Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study. BMC Infectious Diseases, 2021, 21, 1042.	1.3	7
10	A public health strategy for SARS-CoV-2, grounded in science, should guide Swiss schools through the coming winter. Swiss Medical Weekly, 2021, 151, w30086.	0.8	1
11	The epidemic volatility index, a novel early warning tool for identifying new waves in an epidemic. Scientific Reports, 2021, 11, 23775.	1.6	10
12	Transmission of and susceptibility to seasonal influenza in Switzerland from 2003 to 2015. Epidemics, 2020, 30, 100373.	1.5	19
13	Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe. PLoS Medicine, 2020, 17, e1003189.	3.9	120
14	The approximately universal shapes of epidemic curves in the Susceptible-Exposed-Infectious-Recovered (SEIR) model. Scientific Reports, 2020, 10, 19365.	1.6	33
15	Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries. European Journal of Epidemiology, 2020, 35, 389-399.	2.5	210
16	Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries. , 2020, 35, 389.		1
17	Rise and fall of the new variant of <i>Chlamydia trachomatis</i> in Sweden: mathematical modelling study. Sexually Transmitted Infections, 2020, 96, 375-379.	0.8	6
18	Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance, 2020, 25, .	3.9	1,057

#	Article	IF	CITATIONS
19	COVID-19 infectivity profile correction. Swiss Medical Weekly, 2020, 150, w20336.	0.8	77
20	Gini coefficients for measuring the distribution of sexually transmitted infections among individuals with different levels of sexual activity. PeerJ, 2020, 8, e8434.	0.9	6
21	Understanding the spread of de novo and transmitted macrolide-resistance in <i>Mycoplasma genitalium</i> . PeerJ, 2020, 8, e8913.	0.9	8
22	Discrepancies between observed data and predictions from mathematical modelling of the impact of screening interventions on Chlamydia trachomatis prevalence. Scientific Reports, 2019, 9, 7547.	1.6	8
23	Does infection with <i>Chlamydia trachomatis</i> induce long-lasting partial immunity? Insights from mathematical modelling. Sexually Transmitted Infections, 2019, 95, 115-121.	0.8	16
24	Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak. PLoS Neglected Tropical Diseases, 2019, 13, e0007978.	1.3	9
25	The use of mathematical modeling studies for evidence synthesis and guideline development: A glossary. Research Synthesis Methods, 2019, 10, 125-133.	4.2	38
26	Age difference between heterosexual partners in Britain: Implications for the spread of Chlamydia trachomatis. Epidemics, 2018, 24, 60-66.	1.5	4
27	Exploring variation in human papillomavirus vaccination uptake in Switzerland: a multilevel spatial analysis of a national vaccination coverage survey. BMJ Open, 2018, 8, e021006.	0.8	25
28	A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2017, 72, 1961-1968.	1.3	32
29	Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Vaccine, 2017, 35, 7312-7321.	1.7	21
30	Fitness cost and benefit of antimicrobial resistance in Neisseria gonorrhoeae: Multidisciplinary approaches are needed. PLoS Medicine, 2017, 14, e1002423.	3.9	5
31	Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study. BMC Medicine, 2017, 15, 142.	2.3	30
32	How Relevant Is Sexual Transmission of Zika Virus?. PLoS Medicine, 2016, 13, e1002157.	3.9	58
33	Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae. BMC Microbiology, 2016, 16, 216.	1.3	81
34	Potential Impact of Sexual Transmission on Ebola Virus Epidemiology: Sierra Leone as a Case Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004676.	1.3	23
35	Heterogeneity in District-Level Transmission of Ebola Virus Disease during the 2013-2015 Epidemic in West Africa. PLoS Neglected Tropical Diseases, 2016, 10, e0004867.	1.3	27
36	Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners. PLoS Pathogens, 2016, 12, e1005611.	2.1	84

#	Article	IF	CITATIONS
37	P08.34â€Number of sex acts matters for heterosexual transmission and control ofchlamydia trachomatis. Sexually Transmitted Infections, 2015, 91, A145.2-A145.	0.8	0
38	Of mice, macaques and men: scaling of virus dynamics and immune responses. Frontiers in Microbiology, 2015, 6, 355.	1.5	10
39	Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Frontiers in Microbiology, 2015, 6, 1377.	1.5	44
40	Measles Vaccination Coverage and Cases among Vaccinated Persons. Emerging Infectious Diseases, 2015, 21, 1480-1481.	2.0	13
41	Ebola virus disease outbreak in Nigeria: Transmission dynamics and rapid control. Epidemics, 2015, 11, 80-84.	1.5	106
42	Ebola superspreading. Lancet Infectious Diseases, The, 2015, 15, 507-508.	4.6	82
43	Rapid drop in the reproduction number during the Ebola outbreak in the Democratic Republic of Congo. PeerJ, 2015, 3, e1418.	0.9	17
44	Reinfection by untreated partners of people treated for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> : mathematical modelling study. Sexually Transmitted Infections, 2014, 90, 254-256.	0.8	22
45	Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells. PLoS Computational Biology, 2014, 10, e1003871.	1.5	19
46	Estimating the Reproduction Number of Ebola Virus (EBOV) During the 2014 Outbreak in West Africa. PLOS Currents, 2014, 6, .	1.4	321
47	Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling. Health Technology Assessment, 2014, 18, 1-100, vii-viii.	1.3	73
48	Case and partnership reproduction numbers for a curable sexually transmitted infection. Journal of Theoretical Biology, 2013, 331, 38-47.	0.8	11
49	Insights into the timing of repeated testing after treatment for <i>Chlamydia trachomatis</i> : data and modelling study. Sexually Transmitted Infections, 2013, 89, 57-62.	0.8	40
50	Direct and Indirect Effects of Screening for Chlamydia trachomatis on the Prevention of Pelvic Inflammatory Disease. Epidemiology, 2013, 24, 854-862.	1.2	15
51	Transmission of <i>Chlamydia trachomatis</i> through sexual partnerships: a comparison between three individual-based models and empirical data. Journal of the Royal Society Interface, 2012, 9, 136-146.	1.5	63
52	Impaired immune evasion in HIV through intracellular delays and multiple infection of cells. Proceedings of the Royal Society B: Biological Sciences, 2012, 279, 3003-3010.	1.2	11
53	Describing the Progression From Chlamydia trachomatis and Neisseria gonorrhoeae to Pelvic Inflammatory Disease. Sexually Transmitted Diseases, 2012, 39, 628-637.	0.8	29
54	Towards More Robust Estimates of the Transmissibility of Chlamydia trachomatis. Sexually Transmitted Diseases, 2012, 39, 402-404.	0.8	35

CHRISTIAN LORENZ ALTHAUS

#	Article	IF	CITATIONS
55	Timing of progression from Chlamydia trachomatisinfection to pelvic inflammatory disease: a mathematical modelling study. BMC Infectious Diseases, 2012, 12, 187.	1.3	44
56	Individual and Population Level Effects of Partner Notification for Chlamydia trachomatis. PLoS ONE, 2012, 7, e51438.	1.1	32
57	Implications of CTL-Mediated Killing of HIV-Infected Cells during the Non-Productive Stage of Infection. PLoS ONE, 2011, 6, e16468.	1.1	43
58	The Role of Reinfection and Partner Notification in the Efficacy of Chlamydia Screening Programs. Journal of Infectious Diseases, 2011, 203, 372-377.	1.9	59
59	Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy. Molecular Systems Biology, 2010, 6, 348.	3.2	71
60	Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics, 2010, 2, 123-131.	1.5	78
61	Reassessing the Human Immunodeficiency Virus Type 1 Life Cycle through Age-Structured Modeling: Life Span of Infected Cells, Viral Generation Time, and Basic Reproductive Number, <i>R</i> ₀ . Journal of Virology, 2009, 83, 7659-7667.	1.5	44
62	Dynamics of Immune Escape during HIV/SIV Infection. PLoS Computational Biology, 2008, 4, e1000103.	1.5	120
63	Dynamics of CD8+ T Cell Responses during Acute and Chronic Lymphocytic Choriomeningitis Virus Infection. Journal of Immunology, 2007, 179, 2944-2951.	0.4	60
64	Stochastic or deterministic: what is the effective population size of HIV-1?. Trends in Microbiology, 2006, 14, 507-511.	3.5	90
65	Stochastic Interplay between Mutation and Recombination during the Acquisition of Drug Resistance Mutations in Human Immunodeficiency Virus Type 1. Journal of Virology, 2005, 79, 13572-13578.	1.5	85
66	Recombination in HIV and the evolution of drug resistance: for better or for worse?. BioEssays, 2004, 26, 180-188.	1.2	108
67	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 0, , .	13.7	61